Introduction: Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study applies a novel HPV screening tool (previously only used in the oropharynx) to detect HPV DNA directly and determine the prevalence rates in Barrett's oesophagus (BO).
Method: DNA was extracted from 20 formalin-fixed BO samples. HPV DNA was detected using real-time PCR and gel electrophoresis.
Results: 5 out of 20 patients were identified as positive for HPV. Prevalence was 25% in patients with BO.
Conclusion: This method can be used in BO's tissue to determine HPV infection. Adoption of this as a screening test could potentially revolutionise future research in this area. If a clear link between HPV and Barrett's dysplasia can be confirmed, this qPCR method has the potential to aid in monitoring and/or dysplasia detection by stratifying those most at risk and aid in the development of new therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981274 | PMC |
| http://dx.doi.org/10.1136/bmjgast-2021-000840 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Methylated DNA Biomarkers for Potential Non-Endoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.
Am J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background And Aims: We sought to develop a minimally-invasive, robust, accessible nonendoscopic strategy to diagnose Barrett's esophagus (BE), esophageal adenocarcinoma (EAC), and its immediate precursor lesion, high-grade dysplasia (HGD) based on methylated DNA biomarkers applied to a retrievable sponge-capsule device in a cohort representative of the BE population (i.e., mostly short-segment, non-dysplastic BE, NDBE).
View Article and Find Full Text PDFHistological features indicate the risk of progression of patients with Barrett's esophagus.
Pathol Res Pract
January 2025
Department of Pathology and Laboratory Medicine, Penn State Health Hershey Medical Center, Penn State College of Medicine, Hershey, PA 17033, United States. Electronic address:
Our understanding of predictors of progression in Barrett's esophagus (BE) remains incomplete. To address this gap, we evaluated histological features and biomarkers that could predict dysplastic/neoplastic progression in patients with BE. We conducted a retrospective study to identify eligible BE patients and classified the cases into two groups: cases with BE progression (n = 10; progressing to high-grade dysplasia or carcinoma within five years of initial diagnosis) and cases without BE progression (n = 52; without progression to high-grade dysplasia or carcinoma within five years).
View Article and Find Full Text PDFArticle Synopsis
- Endoscopic ablation is the primary treatment for dysplastic Barrett's esophagus (BE), primarily utilizing radiofrequency ablation (RFA) and argon plasma coagulation (APC) in Polish medical centers.
- A retrospective analysis of 160 adult patients revealed high rates of complete remission for intestinal metaplasia (80.0%) and dysplasia (93.8%), alongside a manageable adverse event rate, with 30.6% reporting minor and 5.6% major complications.
- The study also identified that RFA, used more for severe cases, had a higher failure rate compared to APC/h-APC, particularly in patients with long-segment BE and diabetes, suggesting specific risk factors for less favorable treatment outcomes
Time to Therapy May Not Impact Diagnosis Upstaging in Patients Referred for Management of Luminal Gastrointestinal Neoplasia.
Dig Dis Sci
December 2024
Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Center, Mail Stop F735, 1635 Aurora Court, Rm 2.03, Aurora, CO, 80045, USA.
Background: The COVID-19 pandemic dramatically impacted endoscopy practice. Recommendations were to postpone elective cases, including procedures for removal of luminal neoplasia. This provided a natural experiment to evaluate outcomes related to these decisions and the impact of time to procedure on change in histology.
View Article and Find Full Text PDFCryotherapy versus radiofrequency ablation in the treatment of post-chemoradiotherapy patients with recurrence of Barrett's dysplasia.
Clin Endosc
December 2024
Department of Gastroenterology, Cardiff & Vale University Health Board, Llandough, United Kingdom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!